FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") on August 25, 2026, informing the Company that it has regained compliance with the bid price requirement in Listing Rule 5550(a)(2).